SciFluor Life Sciences, LLC Extends License with Harvard University, Secures Technology to Advance and Transform the Use of PET Imaging in Drug Discovery & Development

BOSTON--(BUSINESS WIRE)--SciFluor Life Sciences, a drug discovery and development company harnessing the transformational power of fluorine to accelerate the development of innovative new therapeutics, today announced an agreement with Harvard University that extends its license of proprietary fluorine technology to the rapidly growing field of Positron Emission Tomography (PET) imaging. Under the new agreement, SciFluor gains access to technology that enables the rapid, efficient synthesis of 18F-labeled molecules that empower PET imaging for an entirely new level of intelligent, informed and predictive drug development. The company previously announced an exclusive, worldwide license from Harvard University to various fluorination methods and to a portfolio of novel fluorinated compounds.

Back to news